Clathrin replacement therapeutics

Abstract

The invention in suitable embodiments is directed to replacement therapeutics. In one aspect, a medicament is comprised in whole or in part of one or more clathrin heavy chain protein that is formed from a plurality of isolated, synthetic or recombinant clathrin protein molecules. In one embodiment, a man-made clathrin heavy chain protein composition replaces and/or modifies cell elements or processes, in vivo or in vitro, thereby treating a disease, condition, or disorder comprising at least one of cell.

In view of the foregoing, what is claimed is: 
     
         1 . A pharmaceutical composition for replacement therapy comprising: a man-made non-cage clathrin heavy chain protein that has an amino acid sequence of at least 50, 60, 70, 80, or 90% sequence identity when compared to SEQ ID NO: 1, and administering to a subject in need thereof the preceding protein or composition, and the protein or composition is taken up in whole or in part by a living cell in vivo or in vitro, wherein the protein or composition replaces and/or modifies at least one of cell element or process, and treats a disease, condition, or disorder comprising at least one of cell. 
     
     
         2 . The pharmaceutical composition of  claim 1 , comprising a clathrin light chain protein that is bound to the man-made protein. 
     
     
         3 . The pharmaceutical composition of  claim 1 , comprising one or more cargo elements that are bound to the man-made protein. 
     
     
         4 . The pharmaceutical composition of  claim 1 , comprising one or more additional elements that are incorporated into the man-made protein. 
     
     
         5 . The pharmaceutical composition of  claim 1 , comprising tethers that capture and bind one or more elements to the man-made protein. 
     
     
         6 . The pharmaceutical composition of  claim 1 , comprising receptors that capture and position one or more elements on the man-made protein. 
     
     
         7 . The pharmaceutical composition of  claim 1 , comprising adaptor proteins that are affixed to the man-made protein. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the adaptor proteins are disposed between receptors and the man-made clathrin protein and binding to the receptors. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the one or more cell element or process is located external or internal to cell. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the one or more cell element or process is captured and/or positioned external or internal to cell by the composition or man-made protein. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the one or more cell element or process is replaced and/or modified by the composition or man-made protein. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the man-made protein comprises a multiple of the man-made protein. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the one or more cell comprises a multiple of living cells. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the man-made protein comprises biologically active, biologically modified, chiral, genetically modified, hybridized, isolated, chemically modified, masked, recombinant, synthetic or unmasked protein molecules, or a combination thereof. 
     
     
         15 . The pharmaceutical composition of  claim 1 , wherein the man-made protein has a molecular mass of at least about 170 kilodaltons. 
     
     
         16 . The pharmaceutical composition of  claim 1 , wherein the man-made protein is stable with respect to dissociation. 
     
     
         17 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated for any suitable route and means of administration. 
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein the pharmaceutical composition is formulated as an adhesive, aerosols, a biologic, a capsule, a chemical compound, a coated, crystals, eye drops, gels, an injectable, liquids, oils, ointments, a polymer, powders, a prosthetic, salves, soft galantine capsules, a stent, a controlled release, subcutaneous, surgical, syrups, a tablet, a topical, a vapor, or a water soluble formula. 
     
     
         19 . The pharmaceutical composition of  claim 1 , further comprising a therapeutic agent. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the therapeutic agent is a drug for treating a disease, condition or disorder comprising at least one of cell. 
     
     
         21 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated as an element for use with another element, and one or both of the preceding elements used as a drug for treating a disease, condition, or disorder comprising at least one of cell. 
     
     
         22 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated for targeting a disease, condition, or disorder comprising at least one of cell. 
     
     
         23 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated with acceptable masking agents for reducing immunogenicity and antigenicity. 
     
     
         24 . The pharmaceutical composition of  claim 1 , wherein SEQ ID NO: 1 is substituted with an alternative protein sequence generated from the same gene that generated SEQ ID NO: 1. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the alternative protein sequence includes but not limited to, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. 
     
     
         26 . A method for a pharmaceutical composition for replacement therapy comprising: forming pharmaceutical composition for replacement therapy comprising: a man-made non-cage clathrin heavy chain protein that has an amino acid sequence of at least 50, 60, 70, 80, or 90% sequence identity when compared to SEQ ID NO: 1, and administering to a subject in need thereof the preceding protein or composition, and the protein or composition is taken up in whole or in part by a living cell in vivo or in vitro, wherein the protein or composition replaces and/or modifies at least one of cell element or process, and treats a disease, condition, or disorder comprising at least one of cell.